Mylan Laboratories

• 

  Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients

  The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.

• 

  Foreign Investment Board Clears Mylan's Rs 4,960 Crore FDI Proposal

  Based on the recommendations of FIPB meeting held on July 13, 2015, Mylan Laboratories Ltd's proposal for Rs 4,960 crore FDI has been recommended for approval of CCEA, a Finance Ministry statement said.

• 

  Government Clears FDI Proposals Worth Rs 10,379 Crore

  The investment proposals were approved following the recommendation for the same by the Foreign Investment Promotion Board (FIPB), headed by Finance Secretary Rajiv Mehrishi.

• 

  Dow Surges 263 Points on Pharma Deals, China Stimulus Talk

  Equity markets were also cheered by comments from People's Bank of China governor Zhou Xiaochuan that warned of disinflation and hinted at further monetary easing measures.

• 

  Mylan to Acquire Famy Care's Women's Health Business for $800 Million

  Mylan Inc will acquire certain businesses of Mumbai-based Famy Care Ltd, a specialty women's health care company, for a total consideration of $800 million (over Rs 4,940 crore).

• US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others

  US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

• GlaxoSmithKline's Rs 6,400-crore FDI proposal cleared by investment board: report

  The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.

• Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod

  The acquisition, however, is subject to certain conditions. After the completion of the acquisition process, Mylan has to maintain the investment level in R&D in value terms for five years at absolute quantitative level at the time of induction of FDI, according to sources.

• Government clears 17 FDI proposals worth Rs 262 crore

  The government said on Tuesday that it has cleared 17 foreign direct investment proposals totaling Rs 262.56 crore, including that of Sanofi-Synthelabo (India).

• Pfizer files patent suit against Lupin, 5 other pharma firms

  US-based pharma giant Pfizer Inc today said it has filed suit against six firms, including India's Lupin, over patent infringement of celecoxib, the active ingredient of its branded drug Celebrex used for treating osteoarthritis.

• Government approves 12 FDI proposals worth over Rs 802 crore

  Government today said it has approved 12 foreign direct investment (FDI) proposals, including that of Ratnakar Bank, totaling over Rs 802 crore.

• Why Ranbaxy Laboratories shares hit a 52-week high

  Ranbaxy Laboratories are at a 52-week high on Thursday at Rs 553.50 gaining over 3 per cent over the previous close. We tell you why